Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral enlicitide with rosuvastatin in adults with hyperlipidemia
MOH_2025-10-21_014394Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enlicitide and rosuvastatin in hyperlipidemia (10 arms), sponsored by Merck & Co. Primary endpoint: Percent change in LDL-C at Week 8. Started Oct 2025; status: recruiting.
02
Drugs
enlicitiderosuvastatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on MOH_2025-10-21_014394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-21_014394.